Cambridge Innovation Capital (CIC) has closed its oversubscribed Fund II at £225 million (US$287 million) and is moving from its previous model of open-ended investing to a traditional fixed-term venture capital fund. The money will be dedicated to spinouts from Cambridge University, with CIC investing in series A rounds, but also following on as companies mature and their capital requirements increase.

Biopharmas raising money in public or private financings, including: Exogene, Forcefield, Healome, Hemostemix, Hillevax, Immunocore, Mitorx, Salarius, Savara, Scynexis, Syncona, Takeda.

Biopharmas raising money in public or private financings, Helix, Noxxon.

Biopharmas raising money in public or private financings, including: Bristol Myers Squibb, Dermata, Octant, Xinvento.

Biopharmas raising money in public or private financings, including: Alvotech, Blue Water, Eupraxia, Intensity, Oncomatryx.

Biopharmas raising money in public or private financings, including: Affimed, Biotech Group Acquisition, Crinetics, Foresite Life Sciences, Microviable, Pepgen, Okyo, Oncoquest, Quest, Sionna, Tessera, Trevena.

Biopharmas raising money in public or private financings, including: Kintara, Lixte, Trevena.

Biopharmas raising money in public or private financings, including: Alzheon, Be, Inozyme.